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Background: Diabetes profoundly affects gene expression in organs such as heart, skeletal muscle, kidney and liver,
with areas of perturbation including carbohydrate and lipid metabolism, oxidative stress, and protein ubiquitination.
Type 1 diabetes impairs lung function, but whether gene expression alterations in the lung parallel those of other
tissue types is largely unexplored.
Methods: Lung from a rat model of diabetes mellitus induced by streptozotocin was subjected to gene expression
microarray analysis.
Results: Glucose levels were 67 and 260 mg/dl (p < 0.001) in control and diabetic rats, respectively. There were 46
genes with at least ± 1.5-fold significantly altered expression (19 increases, 27 decreases). Gene ontology groups
with significant over-representation among genes with altered expression included apoptosis, response to stress
(p = 0.03), regulation of protein kinase activity (p = 0.04), ion transporter activity (p = 0.01) and collagen (p = 0.01).
All genes assigned to the apoptosis and response to stress groups had increased expression whereas all genes
assigned to the collagen group had decreased expression. In contrast, the protein kinase activity and ion transporter
activity groups had genes with both increased and decreased expression.
Conclusions: Gene expression in the lung is affected by type 1 diabetes in several specific areas, including
apoptosis. However, the lung is resistant to changes in gene expression related to lipid and carbohydrate
metabolism and oxidative stress that occur in other tissue types such as heart, skeletal muscle and kidney.
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Type 1 diabetes mellitus has widespread adverse effects
on many tissues, including heart, kidney, retina, liver,
vasculature, peripheral nerve and skeletal muscle. These
perturbations contribute importantly to the heightened
morbidity and mortality of subjects with diabetes. The
lung is also affected by type 1 diabetes, manifested by
declines in diffusion capacity, total lung capacity and
forced vital capacity [1-5]. This may contribute to the re-
duced exercise capacity of humans with type 1 diabetes
[6] and account for a portion of the increased sensation
of dyspnea in diabetics when ventilation or respiratory
efforts are increased [7,8]. Nonetheless, severe lung dis-
ease is rarely produced by diabetes, suggesting that the
lung is more resistant than other organs to this disorder.* Correspondence: exv4@cwru.edu
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article, unless otherwise stated.Alveolar microangiopathy is postulated to play a
prominent role in the genesis of diabetes-induced lung
impairment [9]. However, the cellular events leading to
lung impairment, and the reasons for the relative sparing
of the lung compared with other organs such as the kid-
ney and the eye, are not fully understood. One area with
a particular paucity of information is the manner in
which diabetes affects expression of genes in the lung.
This contrasts with the extensive information gleaned
from gene expression array studies of other tissue types,
including pancreas [10], kidney [11-13], liver [14], spleen
[15], adipose tissue [14], eye [16], corpus cavernosum [17],
heart [18-20] and skeletal muscle [14,21-23]. Perturbations
of gene expression by diabetes in these organs are large in
number and magnitude, and cover many cellular processes
such as carbohydrate and lipid metabolism, oxidative stress,
and protein ubiquitination. The purposes of the present
study were to a) determine the changes in gene expressionentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ing alterations in expression of genes in common gene
ontology groups and b) examine the extent to which
affected processes are similar to those reported for other
tissue types or are unique to the lung.Methods
Studies were performed on twelve male Wistar rats ob-
tained from Charles River Laboratories (Wilmington,
MA). All studies were approved by the institutional
animal care and use committee of the Department of
Veterans Affairs (Veterans Health Administration) and
conformed with NIH guidelines for animal care. The
streptozotocin-induced model was similar to that of Hida
et al. [24]. At an age of eight weeks, seven animals were
injected intraperitoneally with streptozotocin 60 mg/kg
dissolved in sodium citrate buffer, and five with buffer
alone. Four weeks later they were well-anesthetized with a
mixture of intraperitoneal ketamine, xylazine and acepro-
mazine following an all-night fast. Blood obtained from
the tail was analyzed for glucose using a glucometer
(Lifescan, Milpitas, CA). Fasting blood glucose values
were 67 ± 4 mg/dl (range 59 to 76) for the normal
animals, and 260 ± 13 mg/dl (range 222 to 313) for
the diabetic animals (P < 0.001 by unpaired t test). Both
lungs from each animal were removed surgically, placed in
RNAlater, and stored at −80°C.
Gene expression array studies were performed similar to
previous investigations from our laboratory [20,25,26].
Total RNA was extracted using Trizol (GibcoBRL,
Rockville, MD), and the RNA pellets were resuspended at 1
μg RNA/μl DEPC-treated water. This was followed by a
cleanup protocol with a Qiagen (Valencia, CA) RNeasy
Total RNA mini kit. Total RNA was prepared for use on
Affymetrix (Santa Clara, CA) microarrays, according to the
directions from the manufacturer. Briefly, 8 μg of RNA was
used in a reverse transcription reaction (SuperScript II;
Life Technologies, Rockville, MD) to generate first strand
cDNA. After second strand synthesis, double strand cDNA
was used in an in vitro transcription reaction to generate
biotinylated cRNA. This was purified and fragmented,
following which 15 μg of biotin-labeled cRNA was used in
a 300 μl hybridization cocktail which included spiked
transcript controls. 200 μl of cocktail was loaded onto
Affymetrix RAE 230A microarrays (Santa Clara, CA) and
hybridized for 16 hr at 45°C with agitation. Standard post-
hybridization washes and double-stain protocols used an
Affymetrix GeneChip Fluidics Station 400. Arrays were
scanned using a Hewlett Packard Gene Array scanner, and
analyzed with Affymetrix MAS 5.0 software. The data have
been deposited in the NCBI Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) and are access-
ible through GEO Series accession number GSE15900.Statistical analysis of the microarray data utilized
Bayesian analysis of variance for microarrays (BAM),
using BAMarray software (http://www.bamarray.com)
[27]. Genes identified by BAM as having significantly
changed expression were then further selected based on
consistent and appropriate present and absent calls per
Affymetrix software. Subsequently signals were averaged
for tissue from the non-diabetic and from diabetic ani-
mals, and fold changes were calculated based on average
values from each group. Analysis focused on genes whose
expression changed at least ±1.5 fold in diabetic compared
with control lung tissue, unless indicated otherwise. To as-
sign biological meaning to the group of genes with chan-
ged expression, the subset of genes which met the above
criteria was analyzed with the Gene Ontology (GO) classifi-
cation system, using DAVID 2.1 software (http://david.abcc.
ncifcrf.gov/) [28,29]. Over-representation of genes with
altered expression within specific GO categories was deter-
mined using the one-tailed Fisher exact probability modi-
fied by the addition of a jackknifing procedure, which
penalizes the significance of categories with very few genes
and favors more robust categories with larger numbers of
genes.
Real-time PCR (RT-PCR) was used to confirm changes
in gene expression as described previously [20,25,26].
Testing was done using the same lung tissue that
had been used for gene expression arrays. An Applied
Biosystems ABI 7900HT unit with automation attach-
ment (Foster City, CA) was used for RT-PCR. This unit
is capable of collecting spectral data at multiple points
during a PCR run. To execute the first step and make arch-
ive cDNA, 3 μg of total RNA was reverse transcribed in a
100 μl reaction using Applied Biosystems enzymes and
reagents in accordance with the manufacturer’s proto-
cols. RNA samples were accurately quantitated using a
Nanodrop Technologies ND-1000 spectrophotometer
(Wilmington, DE). Equal amounts of total RNA were re-
verse transcribed and then used in PCR amplifications.
β-Actin had very little variation in expression across the
sample set and therefore was chosen as the endogenous
control. Since many of the target genes of interest were
signaling molecules and likely to be expressed at low
levels, we opted for a low dilution factor so as to create
an environment more conducive to obtaining reliable
results. The cDNA reaction from above was diluted by a
factor of 10. For the PCR step, 9 μl of this diluted cDNA
was used for each of three replicate 15 μl-reactions car-
ried out in a 384 well plate. Standard PCR conditions
were used for the Applied Biosystems assays: 50°C for
2 min, followed by 95°C for 10 min, followed by 40
cycles of 95°C for 15 sec alternating with 60°C for 1
min each. Values for RNA abundance were normalized
for each gene with respect to the endogenous control
in that sample, mean values for fold changes were
Table 2 Five major specific gene ontology (GO) groupings
with statistically significant over-representation among
genes with at least 1.5-fold changed expression in





Terms Related to collagen
Collagen 3 0.0024
Fibrillar Collagen 2 0.025
Terms Related to Ion Transport
Ion Transporter Activity 8 0.014
Cation Transporter Activity 7 0.016
Terms Related to Apoptosis and
Cell Death
Programmed Cell Death 5 0.025
Death 5 0.026
Cell Death 5 0.026
Apoptosis 5 0.030
Terms Related to Response to Stress
Response to Stress 5 0.033
Terms Related to Regulation of
Kinase Activity
Regulation of Protein Kinase Activity 4 0.036
Regulation of Kinase Activity 4 0.038
Positive Regulation of Protein
Kinase Activity
3 0.048
P values reflect statistical significance of each GO term being over-represented
among genes with altered expression.
(n = 5, 7 for control and diabetic, respectively).
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formed with the unpaired t-test.
Results
There were 46 genes in the lung with diabetes-induced
alterations in gene expression levels of at least ±1.5-fold
(Table 1). For the vast majority of the genes the magni-
tude of the changed expression was in the range of ±1.5-
to ±2-fold, with only 5 genes that had changed expres-
sion exceeding ±2-fold and only 1 gene that had changed
expression exceeding ±3-fold. For the group as a whole,
the number of genes with decreased expression exceeded
the number with increased expression, although the only
gene with a change exceeding ±3-fold was one with in-
creased expression. A complete list of these 46 genes is
provided in Additional file 1: Table S1 [intended for on-
line publication only]. Further analysis was performed
using the group of all genes with at least ±1.5-fold chan-
ged expression.
The 46 genes with altered expression were assigned to
gene ontology (GO) terms using over-representation
analysis. There were five specific GO terms or groups of
closely related GO terms, which ranged in size from
three to eight genes each (Table 2). In addition, there
were a number of considerably more general GO terms
(eg. extracellular region, regulation of biological process,
organismal physiological process), which will not be
considered further here. Of the five specific GO terms
or groups of GO terms, two were characterized by
uniformly increased gene expression (apoptosis and
response to stress), one by uniformly decreased gene
expression (collagen), and two by both increases and
decreases in gene expression (protein kinase activity
and ion transport). For all five the magnitude of
expression changes of the constituent genes did not
exceed ±2-fold. Table 3 lists the individual genes
that belonged to the three GO terms or groups with
uniform directionality of expression changes as well as
their respective fold changed expression values.
Figure 1 compares the number and magnitude of gene
expression changes in the lung with that reportedTable 1 Diabetes altered the expression of a relatively












± 1.5 46 19 27
± 2 5 2 3
± 3 1 1 0
Data are depicted for various fold-change thresholds, and are indicated separately
for all genes with significantly changed expression, just those with increased
expression, and just those with decreased expression. (n = 5, 7 for control and
diabetic, respectively).previously for the heart in a study from our laboratory
that used the same model of type 1 diabetes and the
same methodology as the present study [20]. The heart
had many more genes with diabetes-induced altered ex-
pression than the lung (261 vs. 46 genes, respectively).
Furthermore, the maximum magnitudes of the changes
in expression were higher in the heart than the lung
(range in fold changes of −13.0 to 14.6 vs. -2.6 to 3.8, re-
spectively). Consequentially the disease load index (sum-
mation of the absolute magnitude of fold changes for all
genes with altered expression) [20,30] was considerably
higher for the heart than the lung (583.2 vs. 81.5,
respectively).
Results of RT-PCR studies that confirmed gene ex-
pression array data are depicted in Figure 2. The
direction of the expression changes were identical for
expression array and PCR data, and the gene expression
changes measured by PCR were statistically significant
(range P < 0.05 to P < 0.001). In addition gene array
and PCR data were correlated with each other (r = 0.97,
P < 0.001).
Table 3 Specific genes assigned to the gene ontology








Apoptosis and Cell Death
Lcn2 lipocalin 2 170496 1.94
Gadd45b growth arrest and DNA-damage-
inducible 45 beta
299626 1.73




Prkaa1 protein kinase, AMP-activated,
alpha 1 catalytic subunit
65248 1.58
Response to Stress
Ctgf connective tissue growth factor 64032 1.77
Gadd45b growth arrest and DNA-damage-
inducible 45 beta
299626 1.73
Cd14 CD14 antigen 60350 1.68
Prkaa1 protein kinase, AMP-activated,
alpha 1 catalytic subunit
65248 1.58
Lbp lipopolysaccharide binding protein 29469 1.56
Collagen
Col15a1 procollagen, type XV 298069 −1.88
Col1a1 procollagen, type 1, alpha 1 29393 −1.85
Col3a1 procollagen, type III, alpha 1 84032 −1.70
Figure 1 Gene expression changes with diabetes are compared for th
heart (n = 3, 3 for control and diabetic, respectively). Plotted are fold-c
expression in each of the two tissue types. Heart data are from van Luntere
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The present study used a genome-wide expression ap-
proach to characterize alterations in lung gene expres-
sion by streptozotocin-induced diabetes in rats. Several
specific areas were noted with altered gene expression,
three of which had uniform directional changes (apop-
tosis/cell death, response to stress and collagen) and two
of which had heterogeneous directional changes (protein
kinase activity and ion transport). Nonetheless, the num-
ber of genes with altered expression, and the magnitude
of the changed expression, were modest compared with
findings in most other (albeit not all) tissue types re-
ported previously [13,15-21,31].
Several GO groups of genes with streptozotocin-
induced diabetes altered expression found in the present
lung study have previously been identified in gene ex-
pression array studies of other organ systems. Diabetes-
induced changed gene expression related to apoptosis
and/or cell death has been found in spleen [15], skeletal
muscle [19], and lens [16]. Gene expression changes re-
lated to response to stress have been found in skeletal
muscle [19] and lens [16]. Collagen gene expression
changes have been found in skeletal muscle [21,31], cor-
pus cavernosum [17], and heart [20]. Thus lung and
other tissue types share at least some of the effects of
type 1 diabetes on gene expression.
A previous study found differences among tissue types
(kidney, heart, skeletal muscle and retina) in the effects
of diabetes on gene expression [19]. In the present study,
two gene groups identified as having changed expression
with diabetes in the lung were not identified as havinge lung (n = 5, 7 for control and diabetic, respectively) and the
hange values for each of the genes with at least ±1.5-fold changed
n and Moyer (2007).
Figure 2 Changes in gene expression in diabetic lung measured by RT-PCR are compared with values obtained with gene expression
microarrays. All genes had significantly altered expression by microarrays. (n = 5, 7 for control and diabetic, respectively). Data are well correlated
(r = 0.97, P < 0.001).
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array studies examining other tissues, namely protein kin-
ase activity and ion transport [13,15-21,31]. Conversely,
many GO groups of genes with changed expression in
other tissues were not found to have changed expres-
sion in the lung. One notable area is that of energy
production, including lipid and carbohydrate metabol-
ism, which has been identified as having changed
expression with type 1 diabetes in skeletal muscle
[19,21], heart [18-20], and kidney [19]. Another area is
that of oxidative stress, for which gene expression
changes have been described with type 1 diabetes in
corpus cavernosum [17] and heart [18,20]. One limita-
tion of such direct comparisons of tissue types is
the methodological heterogeneity among studies with
regards to the specific model of type 1 diabetes studied,
the type of gene expression array, and the data analysis and
statistical approaches. However, a previous study of the
heart from our laboratory [20] used the same methodo-
logical strategies as the present study, and identified cardiac
changes related to lipid metabolism, oxidoreductase activity
and calcium ion binding which were not found in the lung
in the present study. This suggests that lung has tissue-
specific gene expression responses to type 1 diabetes in
addition to the shared responses already mentioned.
Among the five GO terms or groups of GO terms identi-
fied as having changed gene expression in the lung with
type 1 diabetes, apotosis/cell death is an attractive candidate
process that may contribute importantly to the genesis of
functional impairment of the lung. Interestingly, insulin in-
hibits apoptosis [32] and furthermore tight glycemic controlaccomplished with exogenous insulin or pancreatic
transplantation attenuates and/or reverses type 1
diabetes-induced pulmonary function abnormalities
[2,33]. Furthermore, osteopontin-deficient mice with
streptozotocin-induced diabetes have milder cardiomy-
opathy and reduced apoptosis compared with wild-
type mice with streptozotocin-induced diabetes [34], sup-
porting the involvement of apotosis in diabetes-induced
organ dysfunction (albeit that of cardiac muscle). However,
genes belonging to the other four GO terms or groups of
GO terms, or even single genes not assigned to specific GO
terms, may very well also play important roles in the
genesis of pulmonary dysfunction with diabetes.
Conclusions
In summary, this study demonstrates that diabetes mellitus
induced by streptozotocin alters gene expression in the
lung of Wistar rats. Directionally uniform changes were
noted for genes involved in three areas, apoptosis/cell
death, response to stress and collagen, whereas directionally
heterogeneous changes were noted for genes involved in
the regulation of protein kinase activity and ion transport.
Equally notable was the absence of changes in some pro-
cesses such as carbohydrate and lipid metabolism that are
implicated in diabetes-induced dysfunction in other tissues.
Additional file
Additional file 1: Table S1. Complete list of genes with statistically
significant changes of at least ±1.5-fold in diabetic compared with normal
lung. (n = 5, 7 for control and diabetic, respectively).
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